Author | David M. Jackman, MD | OncLive

Author | David M. Jackman, MD


Dana-Farber Embraces Pathways in Clinical Practice

November 04, 2018


David M. Jackman, MD, the medical director of Clinical Pathways at Dana-Farber, discusses the benefits of a clinical pathways system.

Dr. Jackman on Overcoming Resistance to EGFR Inhibitors in Lung Cancer

March 27, 2017


David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses overcoming resistance to EGFR inhibitors in non–small cell lung cancer (NSCLC).